# REMS (Risk Evaluation and Mitigation Strategy)

> A safety program the FDA can require for a drug with serious risks, ranging from a medication guide to restricted prescribing and distribution.

Source: https://www.quantisnow.com/glossary/rems
Topic: Glossary / Biotech and FDA
Also known as: REMS, risk evaluation and mitigation strategy, REMS program
Last updated: 2026-10-27

A REMS (Risk Evaluation and Mitigation Strategy) is a drug safety program the FDA can require for certain medications with serious safety concerns, to help ensure the benefits of the drug outweigh its risks. REMS authority was created by the Food and Drug Administration Amendments Act of 2007.

## How it works

The FDA can require a REMS as a condition of approval or later if new safety information emerges. Elements can include:

- **Medication guide** or patient package insert.
- **Communication plan** to inform healthcare providers about risks.
- **Elements to assure safe use (ETASU):** the most restrictive tier, which can require prescriber or pharmacy certification, patient enrollment in a registry, lab testing before dispensing, or dispensing only in certain healthcare settings.

Most REMS include a timetable for assessing whether the program is working, and the FDA can modify or release a REMS over time. A familiar example is iPLEDGE, the REMS for isotretinoin, which requires registration of prescribers, pharmacies and patients because of the risk of birth defects.

## Why it matters for traders

A REMS is part of the label, so the decision on a [PDUFA date](https://www.quantisnow.com/glossary/pdufa-date) is not just "approved or not". Restrictive ETASU programs can slow uptake, limit the number of prescribers and add costs, which can lead analysts to cut sales forecasts even on approval. Conversely, an approval without a REMS when one was feared, or the FDA later removing a REMS, can be a positive surprise.

## Example

Northwind Therapeutics (NWTX) wins approval for a sleep disorder drug, but the label includes a REMS requiring certified pharmacies and patient enrollment. Analysts had modeled $500 million in peak sales; one cuts the estimate by 20% to $400 million, citing slower adoption, and the stock falls despite the approval.

## FAQ

### Does a REMS mean a drug is dangerous?

It means the FDA judged that the drug has serious risks that need extra management to keep its benefits ahead of its risks.

### Can a REMS be removed?

Yes. The FDA can modify or eliminate a REMS if assessments show it is no longer needed.

## Related terms

- [New Drug Application (NDA)](https://www.quantisnow.com/glossary/nda.md): The formal application a drugmaker submits to the FDA requesting approval to market a new small-molecule drug in the United States.
- [Biologics License Application (BLA)](https://www.quantisnow.com/glossary/bla.md): The application a company submits to the FDA to market a biologic, such as an antibody, vaccine or gene therapy, in the United States.
- [PDUFA date](https://www.quantisnow.com/glossary/pdufa-date.md): The target date by which the FDA aims to approve or reject a new drug or biologic application under the Prescription Drug User Fee Act.
- [Complete response letter (CRL)](https://www.quantisnow.com/glossary/complete-response-letter.md): A letter from the FDA stating it cannot approve a drug or biologic application in its current form and explaining the deficiencies to fix.
- [Accelerated approval](https://www.quantisnow.com/glossary/accelerated-approval.md): An FDA pathway approving drugs for serious conditions based on a surrogate endpoint, with confirmatory trials required to verify clinical benefit.

## On Quantisnow

- [Live feed: FDA Approvals](https://www.quantisnow.com/news/fda)
- [FDA approval process](https://www.quantisnow.com/guides/fda-approval-process)